SENTI BIOSCIENCES INC (SNTI)
US81726A1007 - Common Stock
Senti Biosciences Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology...
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
The trading volume of these stocks is deviating from the norm in today's session.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Let's have a look at the gap up and gap down stocks in today's session.
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage...
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – ...
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial...
Senti Bio to Participate in Upcoming Investor Conferences
Senti Bio will participate in two upcoming investor conferences in September....
SNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024
Senti Biosciences just reported results for the second quarter of 2024.
SNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Senti Biosciences (NASDAQ:SNTI) just reported results for the second quarter of...
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – –...
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM)....
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth diving into this morning as we break down all of the biggest news moving shares on Tuesday!
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
The California Institute for Regenerative Medicines (CIRM) has awarded an $8 million grant to Senti Bio to support clinical development of SENTI-202....
Why Is Beyond Air (XAIR) Stock Down 22% Today?
Beyond Air stock is down on Tuesday as investors in XAIR react to the company mixed earnings report for the first quarter of the year.
Why Is Faraday Future (FFIE) Stock Down 27% Today?
Faraday Future stock is down on Tuesday after the troubled EV company announced plans for a reverse split of FFIE shares.
Why Is Senti Biosciences (SNTI) Stock Up 32% Today?
Senti Biosciences stock is up on Tuesday with heavy pre-market trading of SNTI shares despite a lack of news from the company.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202....
SNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024
Senti Biosciences just reported results for the first quarter of 2024.
SNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Senti Biosciences (NASDAQ:SNTI) just reported results for the first quarter of ...
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024....
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202....
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
SNTI stock results show that Senti Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Senti Biosciences (NASDAQ:SNTI) just reported results for the fourth quarter of...